0001562180-20-003063.txt : 20200420
0001562180-20-003063.hdr.sgml : 20200420
20200420175321
ACCESSION NUMBER: 0001562180-20-003063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200417
FILED AS OF DATE: 20200420
DATE AS OF CHANGE: 20200420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reeve Emma
CENTRAL INDEX KEY: 0001680329
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38584
FILM NUMBER: 20803568
MAIL ADDRESS:
STREET 1: C/O PAREXEL INTERNATIONAL CORPORATION
STREET 2: 195 WEST STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CONSTELLATION PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001434418
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-714-0555
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-04-17
false
0001434418
CONSTELLATION PHARMACEUTICALS INC
CNST
0001680329
Reeve Emma
C/O CONSTELLATION PHARMACEUTICALS, INC.
215 FIRST STREET, SUITE 200
CAMBRIDGE
MA
02142
false
true
false
false
Chief Financial Officer
Common Stock
2020-04-17
4
M
false
760.00
6.61
A
760.00
D
Common Stock
2020-04-17
4
S
false
760.00
35.289
D
0.00
D
Stock Option (right to buy)
6.61
2020-04-17
4
M
false
760.00
0.00
D
2027-12-11
Common Stock
760.00
87033.00
D
These trades were made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $35.21 to $35.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on December 11, 2017. The shares underlying the option are scheduled to vest in equal quarterly installments through October 16, 2021.
/s/ Emma Reeve
2020-04-20